Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection

 Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection

Roche Reports New Interim Data of JEWELFISH & RAINBOWFISH Studies for Evrysdi (risdiplam) to Treat Spinal Muscular Atrophy

Shots:

  • The P-III REGN-COV 2069 trial involves assessing the efficacy and safety of Ab cocktail (casirivimab (1200 mg, SC) + imdevimab (1200 mg, SC) vs PBO in 1,505 people to prevent symptomatic infection in household contacts of individuals infected with COVID-19
  • The trial met its 1EP and 2EPs showed an 81% reduction in the risk of symptomatic infections, patients with symptomatic infection resolved symptoms (1 vs 3wk.). In a cohort of infected asymptomatic patients, Ab cocktail showed a 31% reduction in the overall risk of progressing to symptomatic COVID-19
  • The companies will share the results with regulatory authorities including the EMA and the FDA

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: PharmaLive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post